---
document_datetime: 2025-12-16 15:01:52
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/matever-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: matever-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 14.5349476
conversion_datetime: 2025-12-20 17:06:39.494143
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Matever

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number     | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                            |
|------------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------|
| Variation type IA_IN / | C.I.3 Change(s) in the Summary of Product | 16/12/2025                          |                                             | SmPC and PL                      | To update Section 4.6 of the SmPC and Section 2 of |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000319484                     | Characteristics, Labelling or Package Leaflet of human medicinal products intended to implement the outcome of a procedure concerning PSUR or PASS, or the outcome of the assessment done by the competent authority under Articles 45 or 46 of Regulation 1901/2006 - C.I.3.a Implementation of wording agreed by the competent authority - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |                        | the PL to implement the wording agreed by the PRAC following the outcome of the PSUR procedure EMA/PSUR/0000257824 with more recent information on the risk of neurodevelopmental disorders in children exposed prenatally to levetiracetam.                                                                      |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000265766 | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - To update section 4.8 of the SmPC to include additional information on the signs and symptoms of Drug Reactions with Eosinophilia and Systemic Symptoms (DRESS), based on a safety review and after the approval of the same change to the reference product, Keppra. The package leaflet is updated accordingly. Additionally, the MAH took the opportunity to implement editorial changes to the PI in line with the QRD template, remove the local representative for the UK (Northern Ireland), | 16/05/2025 | SmPC, Labelling and PL | To update section 4.8 of the SmPC to include additional information on the signs and symptoms of Drug Reactions with Eosinophilia and Systemic Symptoms (DRESS), based on a safety review and after the approval of the same change to the reference product, Keppra. The package leaflet is updated accordingly. |

<div style=\"page-break-after: always\"></div>